Unit:
Κατεύθυνση Παιδιατρική ΛοιμωξιολογίαLibrary of the School of Health Sciences
Supervisors info:
Βασιλική Παπαευαγγέλου, Καθηγήτρια, Ιατρική Σχολή, ΕΚΠΑ
Μαρία Τσολιά, Καθηγήτρια, Ιατρική Σχολή, ΕΚΠΑ
Νικόλαος Σπυρίδης, Αναπληρωτής Καθηγητής, Ιατρική Σχολή, ΕΚΠΑ
Original Title:
Αξιολόγηση της δοκιμασίας QuantiFERON®-CMV στη συγγενή λοίμωξη από κυτταρομεγαλοϊό
Translated title:
Evaluation of the QuantiFERON®-CMV test in congenital cytomegalovirus infection
Summary:
Cytomegalovirus (CMV) is the most common cause of congenital infection. Congenital CMV infection is usually asymptomatic, and approximately 10% of all neonates will develop clinical disease, including hepatomegaly, splenomegaly, petechiae, neurologic signs (microcephaly, hypotonia, convulsions), and most often, sensorineural hearing loss. Delayed onset hearing loss, neurological and neurodevelopmental sequalae may occur during early childhood.
However, there are no criteria or biomarkers available, to stratify the disease severity. Finding a biomarker that can identify cases in greater risk of developing sequalae would be beneficial to create a more targeted diagnostic and therapeutic approach,
In this prospective study, we aim to investigate the significance of the QuantiFERON®-CMV assay in cases with congenital CMV infection, in which CMV-specific T-cell immunity is tested, through the production of interferon-γ against specific viral antigens. The study was conducted at the 3rd University Pediatric Clinic of the "Attikon" General Hospital, from July 2019 to March 2023 and 31 cases were included.
According to our results the sensitivity and specificity of the QuantiFERON®-CMV assay in detecting the symptomatic newborns with congenital CMV infection were 86.7% and 73.3% respectively. The positive and negative predictive value of the assay were found to be 76.5% and 84.6% respectively. In this study, the trimester of maternal infection, viral load and maternal treatment did not appear to have a statistically significantly correlation to the QuantiFERON®-CMV assay result.
Therefore, the QuantiFERON®-CMV assay could be used as a biomarker to detect those cases that require further targeted investigation with laboratory and/or neuroimaging testing, reducing both cost and parental stress.
Main subject category:
Health Sciences
Keywords:
Congenital infection, Congenital CMV infection, Cytomegalovirus, QuantiFERON-CMV, Interferon
Number of references:
154
File:
File access is restricted until 2024-09-12.
Mavridi_Artemis_MSc.pdf
17 MB
File access is restricted until 2024-09-12.
